Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
| ▸ | LPL | P06858 | 7/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.34 |
| ▸ | FADS1 | O60427 | 2/20 | 0.33 |
| ▸ | F11 | P03951 | 3/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815967 | 0.92 | FFAR1 (0.57) | FFAR1LPLLIPGF11F2 | |
| SCHEMBL4128208 | 0.85 | FFAR1 (0.71) | FFAR1LPLLIPGF11F2 | |
| SCHEMBL15288391 | 0.84 | FFAR1 (0.74) | FFAR1LPLLIPGF11DGAT1 | |
| SCHEMBL2511129 | 0.83 | FFAR1 (0.60) | FFAR1LPLLIPGF11DGAT1 | |
| SCHEMBL20916372 | 0.82 | FFAR1 (0.56) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL1331340 | 0.81 | FFAR1 (0.61) | FFAR1LPLLIPGF11IRAK4 | |
| SCHEMBL9280646 | 0.81 | FFAR1 (0.61) | FFAR1LPLLIPGF11DGAT1 | |
| SCHEMBL26598673 | 0.81 | FFAR1 (0.52) | FFAR1LPLLIPG | |
| SCHEMBL23414888 | 0.81 | FFAR1 (0.74) | FFAR1LPLLIPGF11F2 | |
| SCHEMBL1484925 | 0.80 | FFAR1 (0.60) | FFAR1LPLLIPGF11DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12448396-B2 | Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors | AMGEN INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-02-20 | — | — | US | disclosed |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | APTUIT (VERONA) SRL, AN EVOTEC COMPANY (IT) | 2023-05-25 | — | — | US | disclosed |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | APTUIT (VERONA) SRL, AN EVOTEC COMPANY (IT) | 2023-05-25 | — | — | US | disclosed |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | APTUIT (VERONA) SRL, AN EVOTEC COMPANY (IT) | 2023-05-25 | — | — | US | disclosed |
| US-11512097-B2 | Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2022-11-29 | — | — | US | disclosed |
| EP-4065223-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-4065579-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-2892899-B1 | IMIDAZOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20180072744-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-15 | — | — | US | disclosed |
| US-9914735-B2 | Heteroaryl Syk inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-13 | — | — | US | disclosed |
| WO-2017160632-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017160632-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | disclosed |
| EP-3119765-A1 | HETEROARYL SYK INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3119772-A1 | HETEROARYL SIK INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| US-20160244446-A1 | HETEROARYL SYK INHIBITORS | EVOTEC (UK) LTD. (GB) | 2016-08-25 | — | — | US | disclosed |
| WO-2015140051-A1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140054-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512097-B2 | Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | FFAR1 456/4885LPL 149/4885LIPG 217/4885 |
| US-12448396-B2 | Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors | SCD5, SCD, FADS2 | FFAR1 490/4885LPL 94/4885LIPG 153/4885 |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | SCD5, SCD, FADS2 | FFAR1 490/4885LPL 94/4885LIPG 153/4885 |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | FFAR1 1395/4885LPL 1442/4885LIPG 1293/4885 |
| US-20160244446-A1 | HETEROARYL SYK INHIBITORS | SYK, BTK, IRAK1 | FFAR1 1153/4885LPL 4071/4885LIPG 1960/4885 |
| US-20180072744-A1 | HETEROARYL SYK INHIBITORS | SYK, BTK, CD40 | FFAR1 1076/4885LPL 4010/4885LIPG 2256/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | FFAR1 448/4885LPL 152/4885LIPG 205/4885 |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | FFAR1 950/4885LPL 1381/4885LIPG 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.